Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

748.01 -1.91 (-0.25%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
99 100 Next >
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
From FN Media Group LLC
Via GlobeNewswire
Top 4 Health Care Stocks That May Keep You Up At Night This Month
Via Benzinga
Why Is Eli Lilly Stock Trading Higher Premarket Tuesday?
Shares of Eli Lilly surged as an FDA advisory committee endorsed donanemab, an Alzheimer's treatment shown to significantly impact early-stage patients. The drug's benefits outstripped risks, setting... 
Via Benzinga
Exposures Product Safety
Unpacking the Latest Options Trading Trends in Eli Lilly and Co
Via Benzinga
Market Whales and Their Recent Bets on LLY Options
Via Benzinga
Eli Lilly Hits an All-Time High: Is the Soaring Pharma Stock Still a Buy?
The world's biggest healthcare company might become even larger. 
Via The Motley Fool
Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?
Analysts who follow the start-up drugmaker think its stock has a chance to soar, but that doesn't mean it's right for you. 
Via The Motley Fool
Apple, Meta, Celsius, Eli Lilly, Tesla: Why These 5 Stocks Are On Investors' Radars Today
On Monday, major U.S. indices closed positively, with the Dow Jones Industrial Average rising by 0.2% to 38,868.04. 
Via Benzinga
Topics Stocks
Exposures US Equities
7 Over-Hyped Stocks to Sell Before They Plunge: June Edition
Although these popular names may be hot now, soon the market could agree that they are over-estimated stocks to sell. 
Via InvestorPlace
Eli Lilly Rises Again, As FDA Panel Mulls Biogen-Rivaling Alzheimer's Drug
The FDA isn't bound by the committee's recommendation, but often follows it. 
Via Investor's Business Daily
Exposures Product Safety
What's Happening With Eli Lilly Shares On Monday?
Eli Lilly reports detailed results from the SYNERGY-NASH phase 2 study. The trial, involving 190 patients with and without type 2 diabetes, showed tirzepatide met the primary endpoint, achieving MASH... 
Via Benzinga
Abbott Snags U.S. Clearance To Enter The Obesity Arena, Rivaling Dexcom
The FDA clearance for two new CGMs puts Abbott on track to rival Dexcom's new Stelo device. 
Via Investor's Business Daily
Exposures Product Safety
7 Blue-Chip Stocks to Add to Your June Buy List
There are huge advantages to having blue-chip stocks in your portfolio, particularly when the stock market is on a roll. Consider these. 
Via InvestorPlace
The Company Behind Mounjaro and Zepbound Is Sponsoring Caitlin Clark. Should You Buy the Stock?
One of the most lucrative sports sponsorship opportunities is jersey patches, and one leading pharmaceutical company may have just struck gold. 
Via The Motley Fool
Profiting from the Crowd: 3 Stocks Set to Surge on Retail Investor Enthusiasm
You can use the wisdom of crowds and their fear and greed motives to profit from these three stocks to buy with plenty of room to run. 
Via InvestorPlace
SPDR ETF Report For Friday, June 7
In this video, Ira Epstein reviews the day's trading in various SPDR-ETF markets for the trading day that ended, Friday, June 7. 
Via Talk Markets
Topics ETFs
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Stocks Choppy As 'Higher for Longer' Fed Rhetoric Weighs
Stocks are out of their morning rut, but trading is still choppy to end the week. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Over 10,000 Lawsuits In Novo Nordisk's Ozempic Case Assigned to New Judge
Judge Karen Marston takes over the high-profile Ozempic litigation involving over 10,000 lawsuits. Here's the latest. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Wall Street Reacts To Hot Jobs Report: Stocks Swing As Traders Abandon July Rate Cut Hopes
May labor market report: strong job gains and wage growth, reduces chances of rate cut. Interest-rate sensitive sectors underperform. Top risers: APD, URI, LLY, HUBB, ADP. Top losers: GEN, SHW, FCX,... 
Via Benzinga
Stock Market Revs To Highs On Nvidia, CrowdStrike, Yields: Weekly Review
The Nasdaq and S&P 500 hit record highs, but small caps retreated. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential
New ETFs focusing on weight-loss drugs have launched. However, industry observers caution about their long-term prospects and the concentrated risks associated with these investments. 
Via Benzinga
Topics ETFs
Ozempic, Wegovy Create Domino Effect As New Products Emerge Across Industries To Capture New Consumer Habits
Companies from food and beverage to fitness are adapting to the increased demand for these drugs, hoping to capitalize on shifting consumer habits 
Via Benzinga
Is This Trend a Threat to Eli Lilly's Weight Loss Drug Dominance?
The weight loss drug market is growing rapidly. 
Via The Motley Fool
The 3 Most Undervalued Pharma Stocks to Buy in June 2024
These undervalued pharma stocks to buy are worth a look because even when the economy is struggling, consumers need key medicines. 
Via InvestorPlace
Topics Economy
Exposures Economy
Eli Lilly's Alzheimer's Drug, Donanemab Faces FDA's Adcomm Vote Next Week On Data, Risk Profile
The FDA's advisory committee will review Eli Lilly's Phase 3 study on donanemab for Alzheimer's disease on June 10. This review assesses the drug's benefit-risk profile based on significant efficacy... 
Via Benzinga
Exposures Product Safety
Is Viking Therapeutics Stock a Buy on the Dip?
Short-term thinking is creating an intriguing opportunity for investors. 
Via The Motley Fool
Mid-Year Momentum Plays: 7 Stocks to Buy for the Second Half
Although going with the crowd comes with a certain comfort level, daring investors may want to consider these less-discussed momentum stocks. 
Via InvestorPlace
Growth Stock Goliaths: 7 Picks That Will Tower Over the Competition
Investors who want to put some sizzle in their portfolios should consider investing in these growth names that offer big returns. 
Via InvestorPlace
Chinese Generic Ozempic, Wegovy Versions Could Put Novo Nordisk At The Risk Of Stiff Competition In Key Market
Via Benzinga
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.